{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:45:25Z","timestamp":1783035925432,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the study is to determine that Glycopirrolate is safe and effective in decreasing drooling in children with medical complexity under 3 years of age. Medical treatment is based on anticholinergic drugs as transdermal scopolamine, benzotropine and GLY. GLY (Glycopyrronium bromide) is a synthetic quaternary ammonium anticholinergic agent with poor blood\u2013brain barrier penetration and consequently has limited central effects. Actually, the oral GLY formulation was approved by the United States Food and Drug Administration (FDA) to treat drooling in children aged 3\u201316\u2009years. Five studies reported on GLY use for the treatment of drooling in children with cerebral palsy and other conditions with neurological impairment; four are prospective studies while one a retrospective review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>this is a case report of eighteen children (sex ratio 11\/8, median age 17\u2009months, range 2\u201336\u2009months) under three years of age, followed by a multidisciplinary team at the Bambino Ges\u00f9 Children Hospital. The median follow-up was of 31.5\u2009months (range 1\u201369\u2009months). Response to treatment was assessed according to the Drooling Impact Scale administered at time 0 and after 1\u2009month. All patients have an important neurological impairment: nine patients have a cerebral palsy (Gross Motor Function Classification System class V) and nine a genetic\/malformative syndrome. Twelve patients have a tracheostomy and two need mechanical ventilation. Gastrostomy is present in 16 out of 18 patients. All patients received Glycopirrolate. The median starting daily dose was 0.065\u2009mg\/kg\/die (range 0.02\u20130.21\u2009mg\/kg\/die) three times a day. The drooling impact scale was administered at time O and after 1\u2009month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four out 18 patients stopped treatment for adverse event, lack of efficacy or parental decision. The mean Drooling Impact Scale at time 0 was 89 (range 81\u2013100) and after 1 month 61(range 43\u201378); the difference was statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The overall response to treatment was 94%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to determine the safety and effectiveness of Glycopyrrolate in decreasing drooling in a specific subset of patients. No major side effects were observed. Further comparative studies are needed to confirm our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-021-01195-1","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T11:02:42Z","timestamp":1641639762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glycopyrrolate for drooling in children with medical complexity under three years of age"],"prefix":"10.1186","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-1525","authenticated-orcid":false,"given":"Eleonora","family":"Lovardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"De Ioris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Lettori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Geremia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Staccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gessica Della","family":"Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Scrocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Peppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"issue":"4","key":"1195_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.clinthera.2012.02.026","volume":"34","author":"LS Eiland","year":"2012","unstructured":"Eiland LS. Glycopyrrolate for chronic drooling in children. Clin Ther. 2012;34(4):735\u201342. https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.026.","journal-title":"Clin Ther"},{"key":"1195_CR2","first-page":"CD008624","volume":"11","author":"M Walshe","year":"2012","unstructured":"Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;11:CD008624.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"1195_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/adc.88.10.911","volume":"88","author":"PH Jongerius","year":"2003","unstructured":"Jongerius PH, van Tiel P, van Limbeek J, Gabre\u00ebls FJ, Rotteveel JJ. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child. 2003;88(10):911\u20134. https:\/\/doi.org\/10.1136\/adc.88.10.911.","journal-title":"Arch Dis Child"},{"issue":"4","key":"1195_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/11208120-000000000-00000","volume":"14","author":"KP Garnock-Jones","year":"2012","unstructured":"Garnock-Jones KP. Glycopyrrolate Oral solution for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatr Drugs. 2012;14(4):263\u20139. https:\/\/doi.org\/10.2165\/11208120-000000000-00000.","journal-title":"Paediatr Drugs"},{"issue":"9","key":"1195_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/archpedi.1996.02170340046009","volume":"150","author":"PA Blasco","year":"1996","unstructured":"Blasco PA, Stansbury JC. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med. 1996;150(9):932\u20135. https:\/\/doi.org\/10.1001\/archpedi.1996.02170340046009.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1440-1754.1997.tb00991.x","volume":"33","author":"LM Stern","year":"1997","unstructured":"Stern LM. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health. 1997;33(1):52\u20134. https:\/\/doi.org\/10.1111\/j.1440-1754.1997.tb00991.x.","journal-title":"J Paediatr Child Health"},{"issue":"8","key":"1195_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/000992289803700805","volume":"37","author":"SJ Bachrach","year":"1998","unstructured":"Bachrach SJ, Walter RS, Trzcinski K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr (Phila). 1998;37(8):485\u201390. https:\/\/doi.org\/10.1177\/000992289803700805.","journal-title":"Clin Pediatr (Phila)"},{"issue":"12","key":"1195_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/archpedi.154.12.1214","volume":"154","author":"RJ Mier","year":"2000","unstructured":"Mier RJ, Bachrach SJ, Lakin RC, et al. Treatment of sialorrhea with glycopyrrolate: a double blind, dose-ranging study. Arch Pediatr Adolesc Med. 2000;154(12):1214\u20138. https:\/\/doi.org\/10.1001\/archpedi.154.12.1214.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"1195_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1542\/peds.2010-0910","volume":"127","author":"E Cohen","year":"2011","unstructured":"Cohen E, Kuo DZ, Agrawal R, Berry JG, Bhagat SKM, Simon TD, et al. Children with medical complexity: an emerging population for clinical and research initiatives. Pediatrics. 2011;127(3):529\u201338. https:\/\/doi.org\/10.1542\/peds.2010-0910.","journal-title":"Pediatrics."},{"issue":"24","key":"1195_CR10","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1001\/jama.297.24.2741","volume":"297","author":"JH VanderLee","year":"2007","unstructured":"VanderLee JH, Mokkink LB, Grootenhuis MA, Heymans HS, Offringa M. Definitions and measurement of chronic health conditions in childhood: a systematic review. JAMA. 2007;297(24):2741\u201351. https:\/\/doi.org\/10.1001\/jama.297.24.2741.","journal-title":"JAMA."},{"issue":"2","key":"1195_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1469-8749.2009.03519.x","volume":"52","author":"SM Reid","year":"2010","unstructured":"Reid SM, Johnson HM, Reddihough DS. The drooling impact scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol. 2010;52(2):23\u20138. https:\/\/doi.org\/10.1111\/j.1469-8749.2009.03519.x.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1195_CR12","first-page":"E27","volume":"13","author":"A Mato Montero","year":"2008","unstructured":"Mato Montero A, Limeres Posse J, Tom\u00e1s Carmona I, Fern\u00e1ndez Feijoo J, Diz Dios P. Control of drooling using transdermal scopolamine skin patches A case report. Med Oral Patol Oral Cir Bucal. 2008;13(1):E27\u201330.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"3","key":"1195_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1469-8749.1989.tb04000.x","volume":"31","author":"JA Camp-Bruno","year":"1989","unstructured":"Camp-Bruno JA, Winsberg BG, Green-Parsons AR, Abrams JP. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol. 1989;31(3):309\u201319. https:\/\/doi.org\/10.1111\/j.1469-8749.1989.tb04000.x.","journal-title":"Dev Med Child Neurol"},{"key":"1195_CR14","doi-asserted-by":"publisher","unstructured":"Glycopyrronium for severe drooling in children. Drug Ther Bull. 2017;55(8):93\u20136. https:\/\/doi.org\/10.1136\/dtb.2017.8.0517.","DOI":"10.1136\/dtb.2017.8.0517"},{"issue":"1","key":"1195_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1745-6215-15-60","volume":"5","author":"JR Parr","year":"2014","unstructured":"Parr JR, Weldon E, Pennington L, Steen N, Williams J, Fairhurst C, et al. The drooling reduction intervention trial (DRI): a single blind trial comparing the efficacy of glycopyrronium and hyoscine on drooling in children with neurodisability. Trials. 2014;5(1):60. https:\/\/doi.org\/10.1186\/1745-6215-15-60.","journal-title":"Trials."},{"key":"1195_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/TCRM.S26893","volume":"8","author":"RS Zeller","year":"2012","unstructured":"Zeller RS, Lee HM, Cavanaugh PF, Davidson J. Randomized phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Ther Clin Risk Manag. 2012;8:15\u201323. https:\/\/doi.org\/10.2147\/TCRM.S26893.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-021-01195-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-01195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T11:02:52Z","timestamp":1641639772000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-021-01195-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1186\/s13052-021-01195-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-95070\/v1","asserted-by":"object"}]},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"all the participants and their parents gave informed consent before starting the experimental sessions. The procedure was approved by Ethics Committee of Bambino Ges\u00f9 Children\u2019s Hospital (Rome, Italy).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}